Purpose To develop a population pharmacokinetic model to quantitate the distribution kinetics of glycylsarcosine (GlySar), a substrate of peptide transporter 2 (PEPT2), in blood, CSF and kidney in wild-type and PEPT2 knockout mice. Methods A stepwise compartment modeling approach was performed to describe the concentration profiles of GlySar in blood, CSF, and kidney simultaneously using nonlinear mixed effects modeling (NONMEM). The final model was selected based on the likelihood ratio test and graphical goodness-of-fit. Results The profiles of GlySar in blood, CSF, and kidney were best described by a four-compartment model. The estimated systemic elimination clearance, volume of distribution in the central and peripheral compartments were 0.236 vs 0.449 ml/min, 3.79 vs 4.75 ml, and 5.75 vs 9.18 ml for wild-type versus knockout mice. Total CSF efflux clearance was 4.3 fold higher for wild-type compared to knockout mice. NONMEM parameter estimates indicated that 77% of CSF efflux clearance was mediated by PEPT2 and the remaining 23% was mediated by the diffusional and bulk clearances. Conclusions Due to the availability of PEPT2 knockout mice, we were able to quantitatively determine the significance of PEPT2 in the efflux kinetics of GlySar at the blood-cerebrospinal fluid barrier. 
INTRODUCTION
The blood-cerebrospinal fluid barrier (BCSFB) is formed by choroid plexus epithelial cells of the ventricles and cells of the arachnoid membrane that cover the surface of the brain. Similar to the blood-brain barrier (BBB), the BCSFB protects the central nervous system (CNS) from unwanted toxic compounds in the blood supply to maintain a constant extracellular environment for normal brain function (1, 2) . The BCSFB has several advantages for drug delivery to the brain. First, because of the basolateral infoldings and numerous apical microvilli, choroid plexus epithelial cells have a large surface area for exchange of drug molecules. Second, the tight junctions linking choroid plexus epithelial cells are relatively weak compared to the BBB and, thus, the BCSFB has a relatively high permeability (3) . Third, the BCSFB allows direct access to the ventricles, ependyma and subependymal tissue, leptomeninges, outerlayers of pial vessels, and perivascular spaces (4, 5) . Therefore, the BCSFB can be a useful target for drug delivery to the brain in several CNS disease states. Choroid plexuses possess a variety of transport proteins that act as gate keepers for the inward and outward movement of molecules across the BCSFB. Inwardly directed basolateral transport proteins can facilitate the entry of molecules (e.g., nutrients) into the CSF, whereas outwardly directed apical transport proteins can facilitate the elimination of undesired molecules (e.g., drugs and CSF-born endogenous metabolites) into the blood. The main drug transporters in choroid plexus belong to two superfamilies, the solute carrier (SLC) family including OAT1-3, OATP3 and PEPT2, and the ATP-binding cassette (ABC) carrier family including P-gp and MRP1. The membrane expression of SLC and ABC transporters are polarized and, thereby, allow for efficient movement of drug substrates across the BCSFB (1, 6) . Peptide transporter 2 (PEPT2) is abundantly expressed at the apical surface of choroid plexus epithelia and plays an important role in the efflux of substrate molecules from CSF to blood.
PEPT2 belongs to the proton-coupled oligopeptide transporter (POT) family and is responsible for the cellular uptake of di-and tripeptides in the organism via an inwardly directed electrochemical proton gradient. There are four members of the POT family in mammals: PEPT1, PEPT2, PHT1 and PHT2. Compared to PEPT1, which is a low-affinity and high-capacity transporter, PEPT2 is characterized as a high-affinity and low-capacity transporter (7). PEPT2 is predominantly localized in apical membrane of epithelium in the kidney proximal tubule and brain choroid plexus. It also has been detected in the lung, mammary gland and other tissues of brain (astrocytes, sub-ependymal cells, and ependymal cells). It is generally believed that PEPT2 is responsible for the reabsorption of small peptides and peptide-like drugs in kidney (8) (9) (10) , as well as neuropeptide homeostasis in choroid plexus (11) (12) (13) . Especially in choroid plexus of brain, PEPT2 pumps out peptidomemetic drugs (i.e. cefadroxil) and neuropeptides (i.e. 5-aminolevulinic acid and L-kyotorphin) from CSF into the blood and thereby restricts the delivery of these substrate molecules to the CNS (14) (15) (16) .
Description of CSF pharmacokinetics is important in predicting and understanding pharmacologic actions of CNS drugs (17) . In clinical studies, only limited CSF samples are available per subject because of both medical and ethical reasons, which allows large variation of data in the study. Nonlinear mixed effects modeling (NONMEM) is especially useful in this case to address different sources of variability and to identify major origins of variability. Several studies have developed CSF pharmacokinetic models of drugs using NONMEM data analysis (17) (18) (19) (20) . Since several mechanisms including transport proteins are involved in the influx and efflux of drugs at the brain, quantifying the importance of each distribution mechanism helps us to adjust the dose to meet both the efficacy and safety concerns of CNS drugs. A NONMEM approach can also be a useful tool to parameterize the distribution mechanisms between blood and brain, and to quantatively analyze the importance of different transport proteins as compared to passive processes.
With this in mind, the aim of this study was to develop a population pharmacokinetic model to describe the distribution kinetics of glycylsarcosine (GlySar), a model PEPT2 substrate, at the BCSFB. Our laboratory developed PEPT2-deficient mice, which allows us to study the physiological and pharmacological importance of this transporter in the body (21) . With the use of PEPT2 knockout mice, we developed a distribution kinetics model that incorporated PEPT2 expression level data and quantitatively analyzed the importance of PEPT2 in the efflux mechanism of GlySar at the BCSFB.
MATERIALS AND METHODS
The distribution kinetics of the PEPT2 substrate GlySar was assessed at the BCSFB using nonlinear mixed effects modeling (NONMEM) based on data generated previously in our laboratory (14) . In brief, gender-matched wild-type and PEPT2 knockout mice (6-8 weeks old) were anesthetized with sodium pentobarbital and then administered 100 μl of [ 14 C]GlySar (5 μCi/mouse for labeled GlySar and a total dose of 0.05 μmol/g body weight for both labeled and unlabeled GlySar) by tail vein injection. Blood samples (5 μl) were obtained at 0. 25, 1, 2, 5, 10, 20, 30, 45 , and 60 min after the intravenous bolus via tail nicks. A CSF sample (~5 μl) was collected by inserting a 28-gauge needle into the cisterna magna after the end of sampling. The mouse was then decapitated, and choroid plexuses from lateral and fourth ventricles and whole kidney were harvested. To correct the tissue concentrations of GlySar for vascular space, [ 3 H]inulin (1 μCi/mouse) was administered intravenously 2 min before harvesting the tissues. Tissue samples were weighed and solubilized in 0.5 ml of 1 M hyamine hydroxide for 24 h at 37°C. After solubilization, tissue homogenates, CSF, and blood samples were mixed with Ecolite(+) liquid scintillation cocktail (MP Biomedicals) and the level of radioactivity was measured by a dualchannel liquid scintillation counter (Beckman LS 3801; Beckman Coulter, Fullerton, CA). Corrected tissue concentrations of Glysar (C tissue, corr , nmol/g wet tissue) were calculated as
where C tiss is the uncorrected GlySar tissue concentration (nmol/g), V is the blood volume (ml/g) determined as the inulin space of tissue samples estimated from inulin concentration in the final blood sample (22) , and C b is the GlySar blood concentration (nmol/ml). To investigate time course changes of tissue distributions in choroid plexuses and kidney, the tissue samples were also harvested at preselected time points (2, 5, 15 min) after intravenous administration of [ 14 C]GlySar. [ 3 H]Inulin (1 μCi/mouse) was administered 2 min before harvesting the tissues to correct for the vascular space and all the tissues were processed as previously described.
Non-compartment Analysis of GlySar Pharmacokinetics in Blood
Blood concentration versus time curves of GlySar were initially fit to a non-compartmental model with a weighting factor of unity. Total systemic clearance (CL s ), volume of distibution steady state (V ss ), terminal half-life (t 1/2 ), and mean residence time (MRT) were calculated using the standard methods by WinNonlin version 5.0.1 (Pharsignt Inc., Mountain View, CA).
Population Pharmacokinetic Modeling of GlySar in Blood, CSF, and Kidney
Population pharmacokinetic modeling was carried out using a nonlinear mixed effects modeling approach with NONMEM software, version 7 (ICON Development Solutions, MD, USA). A subroutine ADVAN6 TRANS1 and the first-order conditional estimation were used to build the compartment models throughout the modeling procedure. The best model was determined based on the likelihood ratio test using objective function values (OFV; the lowest value corresponds to the best model) and graphical goodness-of-fit. For nested models, reductions of OFV of at least 3.83 units corresponds to improved fits at p<0.05. Graphical and statistical analysis was implemented using S-Plus 6.2 and R version 2.12.2.
Model Building
A stepwise compartmental model building approach was performed to describe the distribution kinetics of GlySar in the blood, CSF, and kidney. As an initial step, one-, twoand three-compartment models were compared for the Glysar blood concentration-time course after intravenous administration. Nonlinear elimination kinetics have been reported at high doses of PEPT2 substrates possibly associated with a saturation of the reabsorption process in the kidney mediated by PEPT2. Since we only used data in mice following a low dose of GlySar (0.05 mmol/kg), first-order elimination kinetics were assumed in our analysis. Modeling using log-transformed or nontransformed blood concentration data was evaluated and the compartment model with better residual plots was selected.
Once the pharmacokinetic model for blood concentration data was established, the model was extended to include a CSF compartment. It has been shown that PEPT2 is expressed in choroid plexus of the brain and plays a role in transporting drug substrates from CSF to blood (1) . Since GlySar is a PEPT2 substrate, after it enters the brain, the dipeptide can be removed from the CSF of brain to blood by passive diffusion, CSF bulk flow, or active clearance mediated by PEPT2. Therefore, distribution kinetics between the blood and CSF compartments can be parameterized by the following equations (Fig. 1a) :
where A CSF is the amount of GlySar in CSF, A c is the amount of GlySar in central blood, V c is the volume of central compartment, V CSF is the volume of CSF compartment, K in and K out are the inter-compartment rate constants describing GlySar transport between the blood and CSF, K diff, K bulk and K active are distribution rate constants describing GlySar transport between blood and CSF mediated by passive diffusion, CSF bulk flow and PEPT2, respectively, CL diff is the clearance mediated by passive diffusion , CL bulk is the cleara n c e m e d i a t e d b y C S F b u l k f l o w , C L a c t i v e is the active clearance mediated by PEPT2, CL in and CL CSF efflux are the inter-compartment clearances describing GlySar transport between the blood and CSF. CL bulk was set to a physiological value of 0.325 μl/min in mouse (23) . Since PEPT2 is absent in knockout mice, CL diff can be estimated from the knockout animal data. After CL diff was estimated in the model for knockout mice, it was fixed in the model for wild-type mice and the CL active estimated in these animals. Using this stepwise model building process, all parameters for the distribution kinetics between blood and CSF were estimated. The final step was to incorporate a kidney compartment to the model and establish a full pharmacokinetic model, which describes all the distribution and elimination kinetics of blood, CSF and kidney. The estimated kinetic parameters between blood and CSF in the previous step were fixed in this model building process. Since GlySar is only eliminated by kidney, all tissue distribution reservoirs eventually entered the kidney and were eliminated from the body. The full pharmacokinetic model is presented in Fig. 1b and the distribution kinetics between the blood and kidney compartment was modeled as follows:
where A kidney is the amount of GlySar in kidney, K 14 is the distribution rate constant describing GlySar transport from blood to kidney, K 41 is the distribution rate constant describing GlySar transport from kidney to blood, CL s is the systemic clearance, and K 40 is the rate constant describing GlySar elimination from the kidney. K 41 is assumed to be zero in the model, since GlySar is completely renally excreted (14) .
The inter-animal variability for the PK parameters was described by an exponential variance model using the following equation:
where P i is the parameter estimate for the ith animal, P pop is the population estimate of the parameter for a typical animal, and η i is the inter-animal variability representing the inter-animal difference between P i and P pop . The values of η i are assumed to follow a normal distribution with mean of zero and variance ω 2 . All parameters were tested for the necessity of including inter-animal variability. An additive error model was considered for the residual unexplained variability in the log transformed data of GlySar concentration.
Nonparametric Bootstrap Analysis
The stability of the final model was evaluated by nonparametric bootstrap analysis in which 1,000 bootstrap runs were performed using Wings for NONMEM (http://wfn.sourceforge.net). Each bootstrap sample was generated by sampling with replacement from the original sample and the new data set had the same size as the original data set. These 1,000 individual new data sets were fitted to the final model developed from the original data set and bootstrap parameter estimates were obtained from each bootstrap data set. The median, 5th, and 95th percentile of the parameter estimates were calculated from the successful bootstrap runs to obtain a 90% bootstrap confidence interval. Fig. 1 Schematic representation of three-(a) and four-compartment (b) models to simultaneously describe the blood, CSF, and kidney data. Drug molecules are only eliminated by the kidney. K diff, K bulk and K active are distribution rate constants describing GlySar transport between blood and CSF mediated by passive diffusion, CSF bulk flow and PEPT2, respectively.
Visual Predictive Check
The final PK model was also evaluated by visual predictive checks with 1,000 data sets simulated by NONMEM using the parameter estimates of the final model. The median, 5th, and 95th percentiles of the simulated concentrations were calculated at each time point for the blood, CSF and kidney compartments, and visually checked to see if the intervals can cover the observed data points. The visual predictive check plots were generated using R version 2.12.2.
RESULTS

Different Pharmacokinetic Behavior of GlySar Between Wild-Type and PEPT2 Knockout Mouse
GlySar concentrations were significantly lower in the blood and kidney in knockout mice compared to wild-type animals, whereas the CSF concentrations were significantly higher in knockout mice (Fig. 2) . GlySar pharmacokinetic parameters in blood were estimated by a non-compartmental analysis as summarized in Table I . The volume of distribution (V ss ) was slightly increased (p<0.001) and total systemic clearance (CL s ) was increased by almost 2-fold (p<0.001) in knockout mice. Meanwhile, the mean residence time (MRT) was significantly decreased in knockout animals (p <0.05). Since PEPT2 is absent in knockout animals, these changes in GlySar disposition can be attributable to the deletion of PEPT2 functionality (14) . Based on these findings, we decided to develop a model, which describes the distribution kinetics of GlySar in blood, CSF and kidney, and to quantify the importance of PEPT2 in the distribution kinetics of GlySar.
Population Pharmacokinetic Model Building
NONMEM analysis was first performed to fit the blood concentration versus time profile of GlySar using a twocompartment PK model. The expanded model, including CSF, was a three-compartment model as shown in Fig. 1a and the estimated PK parameters of GlySar are listed in Table II . Since our laboratory maintains both wild-type and PEPT2 knockout mice, we were able to study the distribution kinetics and estimate the clearance mediated by passive diffusion (CL diff ), bulk clearance mediated by CSF bulk flow (CL bulk ), and active clearance mediated by PEPT2 (CL active ). The total CSF efflux CL (CL CSF efflux ), which equals the sum of CL diff , CL bulk , and CL active , was 4.3-fold higher for wildtype mice compared to PEPT2 knockout mice, demonstrating that PEPT2 plays an important role as an efflux pump in brain. Based on the estimates, it seems that 77% of CL CSF efflux is mediated by CL active (i.e., by PEPT2) and the remaining 23% is mediated by CL diff and CL bulk . In addition, the estimated CL s values of GlySar for wild-type and PEPT2 knockout mouse were 0.239 and 0.447 ml/min, respectively, which are similar to the results from non-compartmental analysis (Table I ). The V ss values for wild-type (9.52 ml) and PEPT2 knockout mouse (14.2 ml) were also similar to the ones observed from non-compartmental analysis. Therefore, it seems that both the WinNonlin and NONMEM analyses agree on the estimation of pharmacokinetic parameters. The threecompartment model also includes inter-subject variability (% CV) on volume of central compartment (V c , 5.9%), CL diff (36.9%) and CL s (1.4%) for PEPT2 knockout mice, and V c (3.8%) and CL s (2.1%) for wild-type mice.
A four-compartment model was subsequently developed by adding kidney as a separate compartment (Fig. 1b and Table III) . The values of CL diff and CL bulk were fixed in the four-compartment model based on the parameter estimates from the previous threecompartment model. Since GlySar is completely eliminated by the kidney, this organ was regarded as the sole eliminating compartment in the four-compartment model. CL S was almost 2-fold higher for PEPT2 knockout mice compared to wild-type animals, and this is consistent with the results from the three-compartment model. The other estimated parameters of V c , V p , V CSF , CL active , and Q are very similar between the three-compartment (Table II) and four-compartment (Table III) 
Final Model Validation
Basic goodness-of-fit plots for the final four-compartment model are displayed in Fig. 3 . Predicted concentrations of GlySar were highly correlated with observed concentrations in all the blood, CSF and kidney compartments. There were no obvious patterns in the residual plots and the residuals were randomly distributed along the zero line. The final model was further evaluated using a nonparametric bootstrap analysis. Among 1,000 independent runs, 929 and 968 runs were successfully minimized for wild-type and knockout mice respectively. Median estimates and 90% bootstrap confidence intervals of the final model parameters are shown in Table IV . NONMEM estimates were very similar to median values of the bootstrap estimates and were inside of bootstrap confidence intervals (Table III vs  Table IV) , indicating there was no significant bias in the NONMEM parameter estimates. Based on the confidence intervals, V p and CL S were significantly different between wild-type and knockout mice, as was CL CSF efflux , since the confidence interval for CL active does not include zero for wild-type mice.
Visual predictive check plots are shown in Fig. 4 as an additional validation method. It seems that the final model well describes the GlySar concentration-time profiles in the blood, CSF and kidney compartments. Moreover, the 5th and 95th percentiles of simulated results were able to cover almost all the observed data.
DISCUSSION
In the present study, a four-compartment PK model was successfully developed to define the distribution and elimination kinetics of a PEPT2 substrate, GlySar, at the BCSFB. Due to the availability of PEPT2 knockout mice, we were able to quantitatively predict, for the first time, the significance of PEPT2 in the efflux kinetics of a PEPT2 substrate at the blood-CSF interface. In this study, we demonstrated that: 1) the distribution of GlySar in blood, CSF and kidney using nonlinear mixed effects modeling approach is best described by a four compartment model; 2) PEPT2 is responsible for 77% of the total CSF efflux of GlySar at the BCSFB with the remaining 23% being mediated by passive diffusion and CSF bulk flow; and 3) the elimination of GlySar was increased by almost 2-fold in the absence of PEPT2 in knockout mice. CSF is used to predict the extent of CNS penetration of drug molecules since it is easier to collect and analyze compared to other tissues of the brain, and because of ethical constraints in human studies. Drug concentrations in CSF are especially important when the drug target is close to the ventricles, ependyma and leptomeninges, such as in meningitis (24) . The CSF is primarily formed in the choroid plexuses and secreted out of the ventricles into the subarachnoid space. Due to the nature of CSF production and bulk flow, the concentration of compounds that are either produced endogenously in brain or passively diffused from blood to brain are low in CSF (1) . There are also other regulatory mechanisms that can influence drug exchange across the BCSFB such as the tight junctions of choroid plexus, metabolism of drugs at the BCSFB, and the inwardly-or outwardly-directed movement of drug molecules by transport proteins (1) . It has been shown that the morphology of choroid plexus was not changed in PEPT2 knockout mice (21) . Therefore, we were able to assume that CL diff is the same for both wild-type mice and PEPT2 knockout animals. In addition, GlySar is resistant to hydrolysis and excreted from the body in intact form (25) . Thus, metabolic clearance at the BCSFB was assumed to be zero for GlySar. Based on these assumptions, we were able to construct a model that quantitatively separates the three components contributing to the efflux of GlySar at the BCSFB (i.e., CL diff , CL bulk , and CL active ).
To our knowledge, there are no other transporters involved in GlySar uptake into choroid plexus except PEPT2. GlySar may also be transported by PEPT1, PHT1 and PHT2, but there is no molecular or functional evidence to support these transporters having a role in peptide transport systems at the BCSFB (9) . In an isolated choroid plexus study, GlySar uptake was very low in PEPT2 knockout mice (almost 10-fold lower compared to wild-type animals), which demonstrates that no other transporters were significantly involved in GlySar uptake into choroid plexus (13) . When uptake study was performed using choroid plexus epithelial cells in primary culture, GlySar uptake was significantly inhibited by dipeptides and not L-histidine, ruling out the possibility of other transporters participating in GlySar uptake at the apical membrane (14) . At the basolateral membrane, on the other hand, a low affinity uptake process was observed, but the molecular properties of this transporter have not yet been elucidated. Compared to the apical-to-basal transport of GlySar, the reverse transport was very small. Based on this information about di/tripeptide transport mechanisms at the BCSFB, CL in was approximated as CL diff , CL CSF efflux was simplified as the combination of CL diff , CL bulk and CL active , f Inter-subject and residual variabilities were expressed as coefficient of variation (CV%) and CL active was regarded as only being mediated by PEPT2 in our model. The quantitative analysis of efflux mechanisms in the brain is meaningful in that the dose of CNS drugs can be adjusted based on expression levels of relevant transporters. The PEPT2 gene is known to be polymorphically expressed in humans with single nucleotide polymorphisms. For example, the genetic variant R57H of PEPT2 shows a complete loss of transport activity (26, 27) . Based on our estimation that PEPT2 mediates 77% of CSF efflux kinetics for GlySar, we expect the concentrations of this dipeptide to be 4.3-fold greater in CSF during gene deletion. In a previous study, it was shown that CSF-to-blood concentration ratios of GlySar were 4.5-fold higher for PEPT2 null mice compared to wild-type animals (14) . Other studies in our laboratory demonstrated that PEPT2 null mice exhibited 6- and 8-fold greater CSF-to-blood concentration ratios for the PEPT2 substrate, cefadroxil and carnosine, respectively (15, 28) . Additionally, when dose-response studies were performed for L-kyotorphin (L-KTP), an endogenous analgesic neuropeptide and PEPT2 substrate, the ED50 of L-KTP in PEPT2 null mice was five times smaller than in wild-type mice (29) . These findings are in agreement with our present results and suggest that dose adjustments for PEPT2 substrate drugs would be needed for brain drug delivery in patients whose PEPT2 function is disrupted.
It would be valuable if we could extrapolate these findings in mouse to human. PEPT2 is expressed in mouse astrocytes, ependymal cells and choroid plexus epithelial cells of brain (9) , which forms BCSFB, whereas no evidence of PEPT2 expression at the BBB has been reported. Compared to BBB, little is known about the expression levels of transporters at the BCSFB in human, especially for PEPT2. However, peptide transporters including PEPT2 are known to have high homology (about 80%) and similarities in driving forces, substrate specificity and affinity between mouse and human (3, (10) (11) (12) . If it is further elucidated that both species exhibit similar proton gradients across the membrane and similar expression levels of PEPT2 at the BCSFB, then inter-individual differences in CSF pharmacokinetics of peptide-like drugs, due to PEPT2, could also be simulated in humans.
It has been reported that drug transport systems at the BCSFB are altered in CNS diseases, and these alterations may be associated with morphological and/or functional changes of transport proteins. With respect to morphological changes, alterations of choroid plexus microvilli, severe vacuolization, mitochondria alterations and disruption of tight junction complexes have been reported during CNS inflammatory diseases (2, (30) (31) (32) . With respect to functional changes, several reports have shown that the altered function of transport proteins during CNS diseases contributes to changes in the pharmacokinetics of drugs in brain. For example, the active clearance of organic anions in the choroid plexus was strongly impaired by exposure to inflammatory stimuli (33) . It has also been reported that the uptake of benzylpenicillin in choroid plexus was reduced and CSF levels was increased in an experimental meningitis model (33) (34) (35) . These changes can disrupt both the diffusion clearance and active clearance of drugs at BCSFB in our model. Therefore, future studies should be directed at investigating quantitatively any changes in efflux mechanisms during CNS inflammatory diseases.
In addition to CSF, there were differences of GlySar concentrations in the kidney of wild-type and PEPT2 knockout mice, which we successfully incorporated into a fourcompartment model. PEPT2 is highly expressed in the apical membrane of renal proximal tubular epithelium and plays an important role in the reabsorption of small peptides and peptide-like drugs (8) (9) (10) . GlySar is only renally excreted and PEPT2 is involved in the renal elimination of Glysar PEPT1 is also known to be involved in the elimination, especially in the reabsorption of peptide-like drugs, but its contribution is relatively minor compared to PEPT2. It has been previously reported that PEPT2 is responsible for 86% of the reabsorption of GlySar and PEPT1 is responsible for only 14% of the reabsorption (14) . The model with bootstrap dataset estimated CL S values of 0.237 and 0.453 in wild-type and PEPT2 knockout mice, respectively (Table IV) , showing a statistically significant (1.9 fold) difference between the genotypes (p< 0.05). CL S in four-compartment model describes clearance of drug from the blood compartment and, therefore, it reflects the systemic clearance. The predicted value of CL S in fourcompartment model (Table III) was very similar to those value estimated from the non-compartment (Table I ) and the threecompartment model (Table II) . Gene deletion of PEPT2 in knockout mouse disrupts reabsorption of GlySar at the apical membrane of renal epithelium, which eventually results in low concentration of GlySar in blood. It seems that the low blood concentration was then reflected as high value of CL S in knockout mouse. Since GlySar is not actively secreted, has negligible protein binding and golumerular filtration rate is the same for both wild-type and PEPT2 knockout mice (14, 15) , the difference in CL S between wild-type and knockout animal may not be attributable to filtration and secretion at the basolateral membrane of renal epithelium. Peripheral volume (V p ) also shows a 1.6-fold difference in wild-type versus PEPT2 knockout animals in the final model (Tables III and IV) . From the model, peripheral volume is the sum of apparent tissue volumes, which can be expressed as V p ¼ ΣV t f u f u;t , where V t is the apparent tissue volume, f u is the fraction unbound in blood and f u,t is the fraction unbound in tissue. GlySar has negligible protein binding in plasma (14) and, therefore, differences in peripheral volume between wild-type and PEPT2 knockout mice may be mediated by changes in f u,t . PEPT2 is not only expressed in choroid plexus and kidney, but it is also expressed in other tissues such as lung and mammary gland (36) (37) (38) . Therefore, PEPT2 gene deletion in other tissues may affect the increased peripheral volume of GlySar in PEPT2 knockout mice.
CONCLUSION
In conclusion, a population pharmacokinetic model was successfully developed to describe the distribution and elimination kinetics of GlySar, a model PEPT2 substrate, in the blood, CSF and kidney using a nonlinear mixed effects modeling approach. Due to the availability of mice in which the PEPT2 gene is deleted, we were able to quantify the contribution of PEPT2 in the efflux kinetics of GlySar at the BCSFB. In particular, we demonstrated that 77% of the CSF efflux of Glysar was mediated by PEPT2 resulting in approximately 4.3-fold higher CSF concentrations in the PEPT2 knockout mice. Our findings suggest that, given relevant transporter expression levels in tissue, it may be feasible to quantitatively predict the distribution of CNS drugs at the BCSFB and to use this information accordingly for dose adjustments in clinical therapy. Future studies should investigate changes in the distribution kinetics of peptides/mimetics at the BCSFB in disease states such as meningitis, and the possibility of quantifying the impact of such changes on the CSF efflux of peptide-like drugs using a modeling approach.
